Bookmark and Share
Dacarbazine (CID 5351166) - Compound BioActivity Data
.
BioActivity Outcomes:
Active(73)
 
 
Inactive(911)
 
 
Inconclusive(70)
 
 
Unspecified(210)
 
 
Top Targets:
7TM GPCR Srx(36)
 
 
 
7TM GPCR Srsx(30)
 
 
 
p450(25)
 
 
 
 
NR LBD TR(8)
 
 
HSD10-like SD..(8)
 
 
BioAssay Types:
Confirmatory(515)
 
 
 
 
 
Screening(323)
 
 
 
Literature(148)
 
 
 
 
 
BioActivity Types:
Potency(358)
 
 
 
 
 
IC50(145)
 
 
 
 
 
AC50(5)
 
 
 
Data download

Chemical Probe    Active    Inactive    Inconclusive    Unspecified   

Total Bioassays: 1020    Data Row: 1264   Total Pages: 26   Display: Page     
Sort: [Click the result table header to sort]
#SubstanceActivityBioAssayTargetLinks
OutcomeTypeValue [μM]
1
[SID103168962]
IC50 0.556DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2) [AID625178, Type: other]Matrix metalloproteinase-9 [gi:269849668]
View
2
[SID57260110]
IC50 4.86High Throughput Screening Assay used to Identify Novel Compounds that Inhibit Mycobacterium Tuberculosis in 7H9 Media [AID449762, Type: confirmatory]
View
3
[SID57260110]
IC50 5.04A High Throughput Confirmatory Assay used to Identify Novel Compounds that Inhibit Mycobacterium Tuberculosis in the absence of Glycerol [AID449764, Type: confirmatory]
View
4
[SID57260110]
AC50_uM 5.34HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_Dose_CherryPick_Activity [AID687027, Type: confirmatory]PAX8 [Homo sapiens] [gi:998701]
View
5
[SID103168962]
IC50 7.67Cytotoxicity against human GC3/C1 cells after 6 days by MTT assay [AID550849, Type: Literature]
View
6
[SID103168962]
IC50 11.83Cytotoxicity against human UACC62 cells after 6 days by MTT assay [AID550848, Type: Literature]
View
7
[SID103168962]
IC50 14In vitro cytotoxicity against human lymphoblastoid cell (GM892 A) [AID73186, Type: Literature]
View
8
[SID103168962]
IC50 17.67Cytotoxicity against human OVCAR3 cells after 6 days by MTT assay [AID550850, Type: Literature]
View
9
[SID17389952]
Potency 74.978qHTS assay to identify small molecules that stimulate interleukin-8 (IL-8) secretion [AID651758, Type: confirmatory]interleukin 8 [Homo sapiens] [gi:186368]
View
10
[SID103168962]
Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins [AID678712, Type: Literature]Cytochrome P450 1A2 [gi:117144]
View
11
[SID57260110]
HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity [AID652154, Type: screening]PAX8 [Homo sapiens] [gi:998701]
View
12
[SID57260110]
Counterscreen for inhibitors of AddAB: absorbance-based bacterial cell-based high throughput screening assay to identify inhibitors of bacterial viability [AID449728, Type: screening]
View
13
[SID48413510]
DSSTox (CPDBAS) Carcinogenic Potency Database Summary SingleCellCall Results [AID1189, Type: other]
View
14
[SID48413510]
DSSTox (CPDBAS) Carcinogenic Potency Database Salmonella Mutagenicity [AID1194, Type: other]
View
15
[SID48413510]
DSSTox (CPDBAS) Carcinogenic Potency Database Summary Mouse Bioassay Results [AID1199, Type: other]
View
16
[SID48413510]
DSSTox (CPDBAS) Carcinogenic Potency Database Summary MultiCellCall Results [AID1205, Type: other]
View
17
[SID48413510]
DSSTox (CPDBAS) Carcinogenic Potency Database Summary Rat Bioassay Results [AID1208, Type: other]
View
18
[SID48415838]
DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database [AID1195, Type: other]
View
19
[SID57260110]
Counterscreen for AddAB inhibitors: absorbance-based bacterial cell-based high throughput confirmation assay for inhibitors of bacterial viability [AID488956, Type: screening]
View
20
[SID103168962]
DNA inhibitor [AID742711, Type: other]
View
21
[SID99125]
NCI Yeast Anticancer Drug Screen. Data for the rad52 strain [AID147, Type: other]
View
22
[SID99125]
NCI Yeast Anticancer Drug Screen. Data for the wt1 strain [AID149, Type: other]
View
23
[SID99125]
NCI In Vivo Anticancer Drug Screen. Data for tumor model ADJ-PC-6 (intraperitoneal) in BALB/cJ mice [AID184, Type: other]
View
24
[SID99125]
NCI In Vivo Anticancer Drug Screen. Data for tumor model Lymphoma AKR (Transplanted) (intraperitoneal) in AKR/Lw mice [AID190, Type: other]
View
25
[SID99125]
NCI In Vivo Anticancer Drug Screen. Data for tumor model B16 Melanoma (intraperitoneal) in B6D2F1 (BDF1) mice [AID192, Type: other]
View
26
[SID99125]
NCI In Vivo Anticancer Drug Screen. Data for tumor model B16 Melanoma (subcutaneous) in B6D2F1 (BDF1) mice [AID194, Type: other]
View
27
[SID99125]
NCI In Vivo Anticancer Drug Screen. Data for tumor model B16 Melanoma (intraperitoneal) in C57BL/6 mice [AID198, Type: other]
View
28
[SID99125]
NCI Yeast Anticancer Drug Screen. Data for the mgt1 strain [AID153, Type: other]
View
29
[SID99125]
NCI Yeast Anticancer Drug Screen. Data for the rad50 strain [AID155, Type: other]
View
30
[SID99125]
NCI Yeast Anticancer Drug Screen. Data for the mec2-1 strain [AID157, Type: other]
View
31
[SID99125]
NCI Yeast Anticancer Drug Screen. Data for the rad14 strain [AID159, Type: other]
View
32
[SID99125]
NCI Yeast Anticancer Drug Screen. Data for the CLN2oe strain [AID163, Type: other]
View
33
[SID99125]
NCI Yeast Anticancer Drug Screen. Data for the bub3 strain [AID167, Type: other]
View
34
[SID99125]
NCI Yeast Anticancer Drug Screen. Data for the wt2 strain [AID169, Type: other]
View
35
[SID99125]
NCI Yeast Anticancer Drug Screen. Data for the mlh1 strain [AID171, Type: other]
View
36
[SID99125]
NCI Yeast Anticancer Drug Screen. Data for the sgs1 strain [AID173, Type: other]
View
37
[SID99125]
NCI Yeast Anticancer Drug Screen. Data for the rad18 strain [AID177, Type: other]
View
38
[SID99125]
NCI In Vivo Anticancer Drug Screen. Data for tumor model HT29;CX-1 Human Adenocarcinoma (MER+) (intrarenal inoculation) in NU/NU BALB/C (nude) mice [AID208, Type: other]
View
39
[SID99125]
NCI In Vivo Anticancer Drug Screen. Data for tumor model Ependymoblastoma (intracerebral) in B6C3F1 mice [AID226, Type: other]
View
40
[SID99125]
NCI In Vivo Anticancer Drug Screen. Data for tumor model Lymphosarcoma Gardner 6C3HED (intraperitoneal) in C3H/He mice [AID230, Type: other]
View
41
[SID99125]
NCI In Vivo Anticancer Drug Screen. Data for tumor model AK4 Lymphoid Leukemia (intraperitoneal) in C3AKF1 (CHKRF1) mice [AID236, Type: other]
View
42
[SID99125]
NCI In Vivo Anticancer Drug Screen. Data for tumor model Leiomyosarcoma (No. 2) (intraperitoneal) in CAF1 mice [AID238, Type: other]
View
43
[SID99125]
NCI In Vivo Anticancer Drug Screen. Data for tumor model P1081 Chloroleukemia (intraperitoneal) in B6D2F1 (BDF1) mice [AID246, Type: other]
View
44
[SID99125]
NCI In Vivo Anticancer Drug Screen. Data for tumor model L1210 Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice [AID248, Type: other]
View
45
[SID99125]
NCI In Vivo Anticancer Drug Screen. Data for tumor model L1210 Leukemia (subcutaneous) in B6D2F1 (BDF1) mice [AID250, Type: other]
View
46
[SID99125]
NCI In Vivo Anticancer Drug Screen. Data for tumor model L1210 Leukemia (intravenous) in B6D2F1 (BDF1) mice [AID254, Type: other]
View
47
[SID99125]
NCI In Vivo Anticancer Drug Screen. Data for tumor model L1210 Leukemia (intraperitoneal) in CD2F1 (CDF1) mice [AID256, Type: other]
View
48
[SID99125]
NCI In Vivo Anticancer Drug Screen. Data for tumor model L1210 Leukemia (subcutaneous) in CD2F1 (CDF1) mice [AID258, Type: other]
View
49
[SID99125]
NCI In Vivo Anticancer Drug Screen. Data for tumor model Lewis Lung Carcinoma (intravenous) in B6D2F1 (BDF1) mice [AID274, Type: other]
View
50
[SID99125]
NCI In Vivo Anticancer Drug Screen. Data for tumor model Lewis Lung Carcinoma (intravenous) in B6C3F1 mice [AID276, Type: other]
View